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Abstract
Background: Adjuvant chemoradiotherapy is part of a multimodality treatment approach in order to improve
survival outcomes after surgery for gastric cancer. The aims of this study are to describe the results of gastrectomy
and adjuvant chemoradiotherapy in patients treated in a single institution, and to identify prognostic factors that
could determine which individuals would benefit from this treatment.
Methods: This retrospective study included patients with pathologically confirmed gastric adenocarcinoma who
underwent surgical treatment with curative intent in a single cancer center in Brazil, between 1998 and 2008.
Among 327 patients treated in this period, 142 were selected. Exclusion criteria were distant metastatic disease
(M1), T1N0 tumors, different multimodality treatments and tumors of the gastric stump. Another 10 individuals were
lost to follow-up and there were 3 postoperative deaths. The role of several clinical and pathological variables as
prognostic factors was determined.
Results: D2-lymphadenectomy was performed in 90.8% of the patients, who had 5-year overall and disease-free
survival of 58.9% and 55.7%. The interaction of N-category and N-ratio, extended resection and perineural invasion
were independent prognostic factors for overall and disease-free survival. Adjuvant chemoradiotherapy was not
associated with a significant improvement in survival. Patients with node-positive disease had improved survival
with adjuvant chemoradiotherapy, especially when we grouped patients with N1 and N2 tumors and a higher
N-ratio. These individuals had worse disease-free (30.3% vs. 48.9%) and overall survival (30.9% vs. 71.4%).
Conclusion: N-category and N-ratio interaction, perineural invasion and extended resections were prognostic
factors for survival in gastric cancer patients treated with D2-lymphadenectomy, but adjuvant chemoradiotherapy
was not. There may be some benefit with this treatment in patients with node-positive disease and higher N-ratio.
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Introduction
Several Western studies have described a 20-30% 5-year
survival for gastric cancer patients who are treated with
curative intent [1], whereas in Asian countries surgery-
only treated patients have reached 5-year survival near
60%-70% [2,3]. Lymph node dissection seems to have a
major role in this difference, as individuals from West-
ern centers where D2-lymphadenectomy is routinely
performed have survival above 50% [4,5]. Even with opti-
mal surgical treatment, gastric cancer relapse can be
observed in over 40% of the patients [6].
The Intergroup US 0116 Trial (INT 0116) [7] demon-
strated survival improvement with the addition of che-
moradiotherapy after negative-margin resection of
tumors without distant metastases. However, more than
50% of the patients had an incomplete D1 lymph node
dissection, and among the 10% of individuals in whom a
D2-lymphadenectomy was performed, no survival bene-
fit was observed. For these patients, only one prospective
non-randomized study demonstrated a gain of survival
with adjuvant chemoradiotherapy [8]. The interpretation
of this finding is limited by the retrospective analysis
of the study and by conflicting results in the surgical
group [9].
Toxicity is also a major concern in this set of multi-
modality treatment, as performance status is negatively
impacted after gastroesophageal resection [10]. In INT
0116 [7], only 64% of the patients completed treatment
protocol. Another retrospective series demonstrated a
similar pattern of toxicity [11].
The aims of this study are to describe the results of
gastrectomy with or without adjuvant chemoradiother-
apy in gastric cancer patients treated in a single institu-
tion, and to identify prognostic factors that could help
establish subgroups of patients who would benefit from
this treatment.
Materials and methods
Patients
This is a retrospective study, which included patients
with pathologically confirmed gastric adenocarcinoma
who underwent surgical treatment with curative intent
in a single cancer center in Brazil, in the period between
September 1998 and December 2008. Tumor staging
followed the AJCC/UICC TNM staging manual, 7th edi-
tion [12], and lesions staged as IB through IIIC were
included.
Exclusion criteria were: tumors of the gastric stump;
any multimodality treatment different from the INT
0116 protocol [7], distant metastasis and T1N0 tumors.
Patients lost to follow-up or who died postoperatively
were excluded from the analysis.
In the period of our study, 327 patients had surgical
resection for gastric cancer and 142 were analyzed.
Among the excluded individuals, 69 had M1 disease, 50
had T1aN0 or T1bN0 tumors, 19 were diagnosed with
tumors of the gastric stump, 34 received a different mul-
timodality treatment, 10 were lost to follow-up and there
were 3 postoperative deaths. The control group included
patients consecutively treated with surgery only (90),
most of them before 2005, and the other 52 were treated
with resection followed by adjuvant chemoradiotherapy.
Variables
Categories for the following clinicopathological variables
were defined: age, gender, extent of gastric resection,
type of lymphadenectomy, number of dissected nodes,
extended gastrectomy with resection of adjacent or-
gans, tumor site, Lauren`s histological type, T and N
category (TNM 7th ed. [12]), lymphatic vessel and peri-
neural invasion.
The ratio between metastatic and dissected lymph
nodes (N-ratio) was also assessed. The best cut-off inter-
vals were based on the intervals described by Marchet
A. et al. [13] (NR0 – 0%, NR1 – 1%-9%, NR2 – 10%-
25%, N3 -> 25%). In this study, higher survival was
identified in patients with N1 and N2 tumors and lower
N-ratio. In the TNM 7th ed., lesions previously classified
as N1 were divided in N1 (1–2 positive nodes) and N2
(3–6 nodes). The interaction between N-ratio and
N-category was established as described in a previous
study [14]. With the new TNM staging [12], a new
interaction was adopted, with the same intervals for
N2 and N3 tumors and two new intervals for those who
had N1 lesions (NR1a, with an N-ratio of 1-4% and NR1b,
5-9%), since all of them had N-ratio between 1 and 9%.
Surgical treatment
Resection included a distal or total gastrectomy and D2-
lymphadenectomy, as routinely recommended at our
institution. A D1-dissection was only performed in
patients who had poor performance status, in whom a
more extended lymphadenectomy could represent add-
itional operative time and higher morbidity. Pancreatec-
tomy and splenectomy were only performed when
deemed necessary so that negative margins be obtained.
Adjuvant treatment
Gastric cancer patients treated with negative-margin
resections and tumors staged as IB-IV M0 were started
on adjuvant chemoradiotherapy (CT/RT) at our institu-
tion after 2004, according with the protocol described in
the INT 0116 [7]. They should have had performance
status of 2 or lower, adequate renal and liver function
and an appropriate daily caloric intake. Treatment had
to start no more than two months after surgery. All the
patients were treated in 6 Mev Linear Accelerator
with three-dimensional conformal therapy. Four fields
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(antero-posterior and two lateral fields) were used.
Radiotherapy consisted of 45 Gy at 1,8 Gy per day, five
days per week for five consecutive weeks, to tumor bed,
regional nodes and 2 cm beyond the proximal and distal
margins of resection. The tumor bed was defined by pre-
operative computed tomographic imaging.
Survival outcomes
Overall survival was defined as the interval in months
measured between the date of resection and death for
any cause, or the date of the patient`s last appointment.
Disease-free survival was determined as the period be-
tween the date of surgery and the relapse diagnosis,
obtained by imaging tests or as an intraoperative finding,
or death, whichever happened first.
Statistical analysis
For statistical analysis, the software “Statistical Package
for Social Science” (SPSS), version 15.0 was used. The
quantitative variables were expressed by the measure of
appropriate central tendency (mean or median) and re-
spective measure of variability. The comparison of the
two groups regarding their clinicopathological character-
istics was performed by using Student`s t test or
Mann–Whitney test for quantitative data. For qualitative
variables, Pearson`s chi-square or Fisher`s exact test
were used. The analysis of overall and disease-free sur-
vival was done by the estimator product-limit of Kaplan-
Meier and the comparison of curves was done through
log-rank test. The variables that statistically had p<0.20
for the test of log-rank were selected for the multiple
analysis using the Cox proportional hazards model.
Results
Patients and surgical treatment
Among the 142 patients in the study, 81 were male and
their median age was 63 years, ranging from 21 to 88.
Regarding resection, 80 individuals had a total gastrec-
tomy, and the other 62 had a distal gastrectomy. D2-
lymphadenectomy was performed in 129 patients, while
the other 13 had a more limited lymph node dissection
because of poor performance status. The median
number of dissected nodes was 34 (10–84). An extended
gastrectomy was deemed necessary in 26 individuals,
with 22 having splenectomy, 5 distal pancreatectomy,
3 colectomy and 1 left lateral liver resection for
locally advanced disease. Median operative time was
360 minutes (180–840), and only 19 patients had blood
transfusion.
Overall morbidity was 24.6%, including minor and
major postoperative events. The most common events
were pneumonia in 8 patients, intraabdominal abscess in
5, superficial surgical site infection in 5, pancreatic leak-
ing and central line infection in 3 individuals. Median
time of hospital stay was 10 days (6–72). Mortality up to
90 days after surgery was 2.4% (3 cases: 1 due to pneu-
monia, 1 due to complications related to esophagojeju-
nal anastomosis dehiscence and another for pulmonary
thromboembolism).
Pathology findings
The gastric tumors were most frequently located in
the body and antrum (59 and 60 cases, respectively).
Regarding Lauren histological type, 74 patients had in-
testinal tumors, and 68 had diffuse ones. Tumors in-
vading serosa occurred in 85 individuals, and 101 had
lymph node positive disease. The presence of lymph-
atic vessel invasion was observed in 69 patients and 64
had perineural invasion. N-ratio distribution was uni-
form, with slightly higher number of NR0 and NR1
patients.
Clinicopathological features are presented in Table 1,
along with the survival outcomes of the studied
population.
Groups comparison
The group of patients treated with surgery-only, which
was used as a historical control, was compared
with those who received adjuvant chemoradiotherapy.
They were similar when compared by gender, extent of
resection, lymphadenectomy, extended gastrectomy,
tumor site and Lauren histology, number of dissected
nodes, lymphatic vascular invasion, perineural invasion
and T category.
Patients treated with chemoradiotherapy were younger,
with a median of 55 years old, while the surgical group
had a median of 63 years (P<0.001). There was also a
significant difference regarding N-category, as 40% of
the surgery-only patients had N0 disease, whereas there
were only 5 N0 cases (9.6%) in the chemoradiotherapy
group (P>0.001).
Adjuvant therapy
Among the 52 individuals treated with adjuvant chemor-
adiotherapy, 40 completed treatment (76.9%). Regarding
toxicity, 20 patients (38%) had grade II and 8 had grade
III/IV gastrointestinal toxicity, while 19% of them devel-
oped grade III/IV hematological toxicity. Two adjuvant-
related treatment deaths were observed; one patient died
from hematological toxicity while having chemotherapy
associated with radiotherapy, and the other had a
late colonic perforation due to actinic effects, and died
after surgery.
Survival outcomes
The population of the study had a median follow-up of
45 months (49 months for the surgical group and 37 for
the adjuvant CT/RT one). Those who were alive with or
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without recurrence had median follow-up of 56 and 69
months, respectively. Estimated 5-year overall survival
was 58.9%, and 5-year disease-free survival was 55.7%.
Relapse occurred in 47 patients (33.6%), 32 in the
surgery-only group (35.5%) and 15 in the adjuvant treat-
ment one (28.8%). The first documented site of recur-
rence was loco-regional in 23.9%, liver in 30.4%,
peritoneal in 32.6% and other distant sites in 13%.
Patients who received chemoradiotherapy had lower
loco-regional recurrence (21.4% vs. 25%) and a slightly
higher systemic relapse (78.6% vs. 75%), although this
difference was not statistically significant.
The factors that influenced overall and disease-free
survival included: type of gastrectomy, tumor site,
extended resection, lymphatic vessel and perineural in-
vasion, N-ratio, T-category and N-category (Table 1).
Patients who received adjuvant chemoradiotherapy
had 5-year overall survival of 70.9% and disease-free sur-
vival of 59.1%. They had better numbers than the
surgery-only group, which were respectively 54.1% and
53.5%. These results were not statistically significant
though (Figure 1).
For multivariate analysis, the interaction between N-
ratio and N-category was established as described in a
previous study [14] and with the following categories:
N0-NR0; N1-NR1a; N1-NR1b; N2-NR1; N2-NR2 and
NR3; N3a-NR2 and NR3; N3b-NR3. It was an independ-
ent prognostic factor for overall and disease-free
Table 1 Clinicopathological characteristics and prognostic
factors in overall and disease-free survival of patients
treated for gastric cancer
Variable No.
patients
(n=142)
Overall
survival
(5-yr)
P Disease-free
survival
(5-yr)
P
Gender
Male 81 58.7% 0.704 54.1% 0.645
Female 61 58.9% 57.7%
Age
40 years 10 70.0% 0.321 60.0% 0.450
41-69 years 86 62.9% 59.7%
≥ 70 years 46 49.6% 47.5%
Gastrectomy
Total 80 49.7% 0.024 43.9% 0.007
Subtotal 62 70.4% 70.4%
Extended resection
Yes 26 35.5% 0.004 34.6% 0.002
No 116 64.3% 60.6%
Lymphadenectomy
D1 13 50.5% 0.270 47.8% 0.388
D2 129 59.9% 56.3%
No. of dissected nodes
Less than 25 39 54.3% 0.339 48.8% 0.269
25 or more 103 60.6% 58.0%
Location
Cardia 21 37.0% <0.001 27.7% <0.001
Body 59 60.3% 57.9%
Antrum 60 66.8% 64.4%
Linitis 2 0% 0%
Lauren histology
Intestinal 74 61.4% 0.580 57.1% 0.748
Diffuse 68 55.6% 54.1%
Lymphatic vessel invasion
Yes 59 48.8% 0.032 44.7% 0.023
No 83 66.7% 63.8%
Perineural invasion
Yes 67 48.4% 0.015 42.2% 0.003
No 75 68.9% 68.3%
T-category
T1 11 68.6% 0.005 68.6% <0.001
T2 29 78.4% 71.5%
T3 11 61.4% 61.4%
T4a 85 53.8% 51.2%
T4b 6 33.3% 16.7%
Table 1 Clinicopathological characteristics and prognostic
factors in overall and disease-free survival of patients
treated for gastric cancer (Continued)
N-category
N0 40 75.8% 0.002 75.8% 0.005
N1 24 63.8% 57.8%
N2 42 57.7% 53.6%
N3a 29 43.4% 39.3%
N3b 7 14.3% 14.3%
N-ratio
NR0 40 75.8% 0.005 75.8% 0.001
NR1 39 69.8% 66.3%
NR2 27 43.7% 39.9%
NR3 26 36.1% 31.0%
N-category/N-ratio interaction
N0-NR0 40 75.8% 0.002 75.8% 0.001
N1-NR1a 10 76.2% 76.2%
N1-NR1b 14 57.1% 45.7%
N2-NR1 15 79.0% 79.0%
N2-NR2 and NR3 27 45.1% 39.5%
N3a-NR2 and NR3 29 43.4% 39.3%
N3b-NR3 7 14.3% 14.3%
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survival, along with extended gastrectomy and peri-
neural invasion (Table 2).
The role of adjuvant chemoradiotherapy in
survival outcomes
In order to identify a specific group of patients who
would benefit from this set of adjuvant treatment, its in-
fluence in survival for all categories of every prognostic
factor identified in univariate analysis was tested.
Patients who had lymph node metastasis had a signifi-
cant improvement in overall survival (P=0.023) with the
addition of adjuvant chemoradiotherapy. The same
benefit was not observed in any other category
(Table 3).
The role of this multimodality treatment was then
tested in different groups of patients who had lymph
node metastasis, by using the N-category – N-ratio
interaction. Patients with N1 and N2 tumors and higher
N-ratio had similarly superior survival numbers with the
addition of chemoradiotherapy (Table 3), but this data
was not statistically significant. These 65 individuals
were then divided in two groups, one including 25
patients with N1-NR1a or N2-NR1 disease (Group 1),
and 40 with N1-NR1b or N2-NR2 and NR3 disease
(Group 2). No statistical differences between the groups
were observed (Table 4). The individuals in Group 1,
with a lower N-ratio, had no benefit with adjuvant che-
moradiotherapy both in overall (78.8% vs. 76.9%) and
disease-free survival (81.8% vs. 76.9%), whereas those in
Group 2 who had adjuvant treatment had a significant
improvement in overall survival (71.4% vs. 30.9%;
P=0.038) and superior but not statistically significant
numbers regarding disease-free survival (48.9% vs.
30.3%; P=0.145).
Discussion
Adjuvant chemoradiotherapy after complete resection
for gastric cancer was associated with an improvement
in overall and disease-free survival [7] and has been
adopted in many Western centers since [15]. Some
issues should be addressed though, surgical control being
the major one. In the INT0116, D2-lymphadenectomy
Figure 1 Overall and Disease-free survival of gastric cancer patients treated with surgery with or without adjuvant chemoradiotherapy.
Table 2 Multivariate analysis prognostic factors in overall
and disease-free survival of patients treated for gastric
cancer
Variable Overall survival Disease-free survival
HR (CI 95%) P HR (CI 95%) P
Perineural invasion
No 1.0 1.0
Yes 2.03 (1.17-3.53) 0.011 2.46 (1.46-4.15) 0.00
Extended resection
No 1.0 1.0
Yes 2.40 (1.31-4.38) 0.004 2.58 (1.46-4,56) 0.001
Treatment modality
Surgery only 1.61 (0.85-3.04) 0.142 * *
Adjuvant CT/RT 1.0 * *
N-category – N-ratio
N0-NR0 1.0 0.021 1.0 0.008
N1-NR1a 0.72 (0.16-3.17) 0.661 0.65 (0.15-2.86) 0.568
N1-NR1b 1.92 (0.73-5.05) 0.184 2.01 (0.81-4.96) 0.131
N2-NR1 0.51 (0.14-1.81) 0.297 0.41 (0.20-1.44) 0.167
N2-NR2 and NR3 2.02 (0.93-4.39) 0.076 2.26 (1.10-4.63) 0.026
N3a – NR2 and NR3 2.78 (1.31-5.89) 0.008 2.66 (1.30-5.44) 0.007
N3b – NR3 2.96 (1.08-8.12) 0.036 2.77 (1.03-7.44) 0.043
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was recommended as part of the surgical treatment.
However, it was performed in only 10% of the patients,
who had a median survival of 48 months and no im-
provement with adjuvant treatment, whereas the whole
study population had median survival of 36 months [7].
The use of this treatment in patients who had D2-
lymphadenectomy was first reported in a nonrando-
mized Korean study with 890 patients, in which adjuvant
treatment was associated with an improvement in sur-
vival (57% vs. 51%). This same group led the just
published ARTIST Trial, a phase III study that com-
pared the adjuvant treatment with chemotherapy (6
cycles of XP - Capecitabine and Cisplatin) vs. the associ-
ation of chemotherapy and radiotherapy (2 cycles of XP +
XP and Radiotherapy + 2 more cycles of XP) after D2-
lymphadenectomy. The addition of radiotherapy provided
an improvement in disease-free survival for node-
positive patients [16].
Patterns of relapse are another point of concern. In
the INT 0116 trial, adjuvant chemoradiotherapy was
Table 3 Survival outcomes stratified by prognostic factors in overall and disease-free survival of patients treated for
gastric cancer with or without adjuvant chemoradiotherapy
Variable No. patients Overall survival P Disease-free survival P
Surgery
only (n=90)
Adjuvant
CT/RT (n=52)
Surgery
only
Adjuvant
CT/RT
Surgery
only
Surgery
CT/RT
Lymphatic Vessel Invasion
Yes 39 20 43.1% 65.8% 0.198 39.5% 41.7% 0.567
No 51 32 62.3% 76.8% 0.458 61.6% 68.8% 0.735
Perineural Invasion
Yes 47 20 43.7% 62.9% 0.470 40.7% 42.8% 0.787
No 43 32 64.0% 79.2% 0.222 63.1% 71.7% 0.603
Extended resection
Yes 18 8 33.3% 45.0% 0.546 33.3% 37.5% 0.951
No 72 44 59.0% 76.2% 0.219 58.5% 63.4% 0.486
Lymph node metastases
Yes 55 46 40.6% 68.2% 0.023 40.6% 53.7% 0.113
No 35 6 73.4% 100.0% 0.736 73.4% 50.0% 0.716
T-category
T1 4 7 75.0% 66.7% 0.627 75.0% 66.7% 0.627
T2 21 8 70.6% 100.0% 0.096 70.6% 71.4% 0.629
T3 5 6 25.0% 85.7% 0.081 25.0% 83.3% 0.170
T4a 55 30 51.3% 62.0% 0.875 50.1% 52.4% 0.999
T4b 5 1 20.0% 100.0% 0.259 20.0% 0.0% 0.953
N-category
N0 35 5 73.4% 100.0% 0.736 72.4% 100.0% 0.689
N1 14 10 50.0% 80.0% 0.203 50.0% 52.5% 0.674
N2 22 20 46.5% 73.1% 0.140 45.0% 64.3% 0.279
N3a 14 15 32.7% 58.7% 0.340 32.7% 41.7% 0.439
N3b 5 2 16.7% 0.0% 0.758 16.7% 0.0% 0.919
N-category – N-ratio
N0 – NR0 35 5 73.4% 100.0% 0.736 72.4% 100.0% 0.689
N1 – NR1a 5 5 80.0% 75.0% 0.688 80.0% 75.0% 0.688
N1 – NR1b 9 5 37.5% 83.3% 0.106 37.5% 40.0% 0.553
N2 – NR1 8 7 75.0% 83.3% 0.620 75.0% 85.7% 0.656
N2 – NR2 and NR3 14 13 27.8% 67.7% 0.120 26.8% 53.8% 0.251
N3a – NR2 and NR3 14 15 32.7% 58.7% 0.340 32.7% 41.7% 0.439
N3b – NR3 5 2 16.7% 0.0% 0.758 16.7% 0.0% 0.919
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associated with a decrease in local recurrence (29% vs.
19%), but not in systemic/peritoneal relapse. A large
Eastern series with 2328 patients described loco-regional
relapse to be around 20% with surgery only [17].
Even Western studies demonstrate that when D2-
lymphadenectomy is performed less than 20% of the
patients develop loco-regional recurrence [18].
Debates remain among some Western authors regard-
ing the extent of lymphadenectomy for gastric can-
cer. They are based in the negative results of two
randomized trials published in 1999. Their results
should be interpreted with caution, mainly due to the
adverse effect of D2-related pancreatic and splenic resec-
tions in postoperative mortality. A recent update in the
results of one of these trials should put an end to this
controversy, as D2-lymphadenectomy was associated
with a significant improvement in cancer-related mortal-
ity and in loco-regional recurrence [19].
The present study included 90.8% of patients who
were treated with D2 dissection. Severe postoperative
morbidity was low and postoperative deaths were
excluded, which suggests that the number of patients
who were programmed to have adjuvant chemora-
diotherapy and did not receive it was very low. The
treatment was not associated with significant improve-
ment in overall and disease-free survival. Some limita-
tions about this finding should be discussed. The first
one regards the two differences between the group of
patients treated with resection, and the ones treated with
adjuvant chemoradiotherapy, who were younger and had
higher frequency of node-positive tumors. In this case,
treatment could offset a worse result in patients with
node-positive disease. Another limitation of the study
resides in the fact that this is a retrospective cohort of
consecutive cases and the more recently treated indivi-
duals were the ones who had adjuvant chemoradiother-
apy and, therefore, have a shorter follow-up. The use of
a historic control may represent another bias, albeit the
low morbidity and mortality of patients throughout the
study and the fact that all the patients were operated by
the same group of surgeons.
Based on the conflicting results in the literature on the
subject of chemoradiotherapy in patients treated with
D2-lymphadenectomy, the toxicity it is associated with,
and this own series numbers, which showed better
but not significant results with adjuvant treatment, the
goal was to try to identify prognostic factors that could
establish which individuals would benefit from adjuvant
treatment.
Besides extended resections, perineural invasion was
also an independent prognostic factor associated with
worse survival, as has been shown in the literature, espe-
cially if associated with lymphatic vessel invasion and
early tumors [20].
However, the most important prognostic factor for
overall and disease-free survival was the interaction be-
tween N-category and N-ratio. It has been shown that
this interaction individualizes groups of patients with
distinguished survival numbers within the same N-
category in TNM staging 6th edition [14], confirming the
finding in other studies that N-ratio could determine dif-
ferent outcomes in patients with N1 and N2 tumors
[13,21]. The role of this interaction was now investigated
in the new TNM staging system 7th edition [12] and
again different survival outcomes were identified in
Table 4 Clinicopathological characteristics of the two
N-category / N-ratio groups determined
Variable Group 1
(N1-NR1a N2-NR1)
Group 2
(N1-NR1b N2-NR2 and NR3)
P
Gender
Male 10 25 0.077
Female 15 15
Age
Mean 60,1 64,2 0.249
Gastrectomy
Total 14 23 0.905
Subtotal 11 17
Extended resection
Yes 21 32 0.477
No 4 8
No. of dissected nodes
Median 40 (23–69) 28 (10–50) <0.001
Location
Cardia 1 9 0.130
Body 11 15
Antrum 13 16
Lauren histology
Intestinal 12 21 0.724
Diffuse 13 19
Lymphatic vessel invasion
Yes 9 16 0.747
No 16 24
Perineural invasion
Yes 12 15 0.403
No 13 25
T category
T1 5 2 0.286
T2 4 8
T3 3 3
T4a 11 25
T4b 2 2
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patients with N1 and N2 tumors (N2-NR2 and NR3
tumors – HR 2.02 for death and 2.26 for recurrence).
When analyzing the role of adjuvant chemoradiother-
apy for each variable category, an improvement in over-
all survival among patients with node-positive disease
was observed. However, by studying the distribution of
these patients in different N-category N-ratio categories,
individuals with N1 and N2 lesions and higher N-ratio
seemed to have better survival with adjuvant chemora-
diotherapy. By grouping these patients, this difference in
outcomes was more easily identified, with a significant
improvement in overall and better numbers albeit not
statistically significant in disease-free survival. Those
who had D2-lymphadenectomy with higher N-ratio had
the worse outcomes, possibly because residual node dis-
ease was left behind. To measure the likelihood of dis-
ease in undisected regional nodes, the use of the
Maruyama index (MI) has already been described. An
MI < 5 was an independent survival prognostic factor
among the INT0116 patients and it proved to be a valu-
able surgical undertreatment detection tool [22].
The most important limitation in our study refers to
the small number of patients, especially in the subgroups
of N1/N2 tumors, with 65 in total. This may provide a
low statistical power for the results. However, even in
this small subset, very different numbers were observed
and a statistically significant result was obtained, which
favored the rationale of using N-ratio associated with N-
category to help identify patients who supposedly had a
D2-lymphadenectomy and would benefit from adjuvant
chemoradiotherapy. This interaction worked as a
numeric criterion that might represent, after further
studies, an absolute, reproducible factor that could help
select patients for this treatment could have been
established.
In conclusion, in this single center series, adjuvant
chemoradiotherapy was not a prognostic factor for over-
all and disease-free survival in gastric cancer patients
treated with D2-lymphadenectomy. Patients with N1
and N2 tumors and higher N-ratios could benefit from
this multidisciplinary treatment.
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